JPWO2020249979A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249979A5 JPWO2020249979A5 JP2021571935A JP2021571935A JPWO2020249979A5 JP WO2020249979 A5 JPWO2020249979 A5 JP WO2020249979A5 JP 2021571935 A JP2021571935 A JP 2021571935A JP 2021571935 A JP2021571935 A JP 2021571935A JP WO2020249979 A5 JPWO2020249979 A5 JP WO2020249979A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- aenh
- acute
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 230000001154 acute effect Effects 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000028185 Angioedema Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 206010019860 Hereditary angioedema Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 101800004538 Bradykinin Proteins 0.000 claims 4
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 4
- 102100035792 Kininogen-1 Human genes 0.000 claims 4
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 3
- 230000008961 swelling Effects 0.000 claims 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 3
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 2
- 102100034869 Plasma kallikrein Human genes 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- 206010013952 Dysphonia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000010473 Hoarseness Diseases 0.000 claims 1
- 206010027951 Mood swings Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005707 acquired angioedema Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000003915 air pollution Methods 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000035824 paresthesia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861758P | 2019-06-14 | 2019-06-14 | |
| US62/861,758 | 2019-06-14 | ||
| GBGB1910125.2A GB201910125D0 (en) | 2019-07-15 | 2019-07-15 | Treatments of angioedema |
| GB1910125.2 | 2019-07-15 | ||
| PCT/GB2020/051441 WO2020249979A1 (en) | 2019-06-14 | 2020-06-15 | Treatments of angioedema |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022537913A JP2022537913A (ja) | 2022-08-31 |
| JP2022537913A5 JP2022537913A5 (https=) | 2023-07-27 |
| JPWO2020249979A5 true JPWO2020249979A5 (https=) | 2023-07-27 |
| JP7640474B2 JP7640474B2 (ja) | 2025-03-05 |
Family
ID=67700187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571935A Active JP7640474B2 (ja) | 2019-06-14 | 2020-06-15 | 血管性浮腫の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220226293A1 (https=) |
| EP (1) | EP3982961A1 (https=) |
| JP (1) | JP7640474B2 (https=) |
| KR (1) | KR20220024221A (https=) |
| CN (2) | CN113993520A (https=) |
| AR (1) | AR119159A1 (https=) |
| AU (1) | AU2020293616A1 (https=) |
| BR (1) | BR112021024447A2 (https=) |
| CA (1) | CA3142220A1 (https=) |
| CL (2) | CL2021003243A1 (https=) |
| GB (1) | GB201910125D0 (https=) |
| IL (1) | IL288612A (https=) |
| MA (1) | MA56188A (https=) |
| MX (1) | MX2021014558A (https=) |
| PH (1) | PH12021552967A1 (https=) |
| SG (1) | SG11202113375PA (https=) |
| TW (1) | TW202112371A (https=) |
| WO (1) | WO2020249979A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| US20250281397A1 (en) | 2022-04-27 | 2025-09-11 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| EP2590945B1 (en) | 2010-07-07 | 2014-04-30 | The Medicines Company (Leipzig) GmbH | Serine protease inhibitors |
| US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| MY174018A (en) | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| HUE057912T2 (hu) * | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
-
2019
- 2019-07-15 GB GBGB1910125.2A patent/GB201910125D0/en not_active Ceased
-
2020
- 2020-06-15 MA MA056188A patent/MA56188A/fr unknown
- 2020-06-15 JP JP2021571935A patent/JP7640474B2/ja active Active
- 2020-06-15 US US17/617,456 patent/US20220226293A1/en not_active Abandoned
- 2020-06-15 CN CN202080043658.4A patent/CN113993520A/zh active Pending
- 2020-06-15 AU AU2020293616A patent/AU2020293616A1/en not_active Abandoned
- 2020-06-15 MX MX2021014558A patent/MX2021014558A/es unknown
- 2020-06-15 SG SG11202113375PA patent/SG11202113375PA/en unknown
- 2020-06-15 PH PH1/2021/552967A patent/PH12021552967A1/en unknown
- 2020-06-15 EP EP20734285.8A patent/EP3982961A1/en not_active Withdrawn
- 2020-06-15 CA CA3142220A patent/CA3142220A1/en active Pending
- 2020-06-15 WO PCT/GB2020/051441 patent/WO2020249979A1/en not_active Ceased
- 2020-06-15 CN CN202410143627.6A patent/CN118078821A/zh active Pending
- 2020-06-15 BR BR112021024447A patent/BR112021024447A2/pt unknown
- 2020-06-15 KR KR1020217043375A patent/KR20220024221A/ko not_active Withdrawn
- 2020-06-15 TW TW109120109A patent/TW202112371A/zh unknown
- 2020-06-16 AR ARP200101682A patent/AR119159A1/es not_active Application Discontinuation
-
2021
- 2021-12-02 IL IL288612A patent/IL288612A/en unknown
- 2021-12-06 CL CL2021003243A patent/CL2021003243A1/es unknown
-
2023
- 2023-03-10 CL CL2023000699A patent/CL2023000699A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3982960T3 (fi) | Perinnöllisen angioödeeman hoitoja | |
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| MXPA06012116A (es) | Uso de flibanserina en el tratamiento del trastornos premestruales y otros trastornos sexuales femeninos. | |
| CA3107624C (en) | Composition for eradicating helicobacter pylori | |
| RU2012121185A (ru) | Фармацевтические композиции комбинаций ингибиторов дипептидилпептидазы-4 с пиоглитазоном | |
| JPWO2020249977A5 (https=) | ||
| CN100376245C (zh) | 结合有泰妥拉唑与消炎剂的药物组合物 | |
| Ventafridda et al. | Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs | |
| CN102036669B (zh) | 用于治疗早泄的药物组合物 | |
| CN118401241A (zh) | 用于治疗慢性肾脏病的醛固酮合成酶抑制剂 | |
| WO2012178014A1 (en) | Compositions and methods for treatment of chronic fatigue | |
| JPWO2020249979A5 (https=) | ||
| US20080194877A1 (en) | Benzamidine Derivatives for Treatment and Prevention of Cancer Therapy Induced Mucositis | |
| CN103599115B (zh) | 一种组合物在制备抗癫痫药物中的应用 | |
| CN1509178A (zh) | 一种包括溶血磷脂酸的药用组合物 | |
| AU2011283462B2 (en) | Therapeutic agent or prophylactic agent for neuropathic pain | |
| CN1250218C (zh) | 血管紧张素拮ⅱ抗剂的新用途 | |
| NZ782935B2 (en) | Treatments of hereditary angioedema | |
| TWI668005B (zh) | 逼尿肌過度活動伴收縮力降低之改善劑 | |
| EP1519728B1 (en) | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder | |
| CN1893942A (zh) | 加波沙朵治疗失眠症的用途 | |
| CN102327599A (zh) | 用于治疗骨髓增生异常综合征的组合物和方法 | |
| US7470690B2 (en) | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder | |
| US20060241136A1 (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| RU2545687C1 (ru) | Способ эрадикации хеликобактер пилори гастродуоденальной зоны |